Research Article

Minority Breast Cancer Survivors: The Association between Race/Ethnicity, Objective Sleep Disturbances, and Physical and Psychological Symptoms

Pinky H. Budhrani,^{1,2} Cecile A. Lengacher,² Kevin E. Kip,²
Cindy Tofthagen,² and Heather Jim³

¹ Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA 02215, USA

² University of South Florida College of Nursing, Tampa, FL 33612, USA

³ H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA

Correspondence should be addressed to Pinky H. Budhrani; pinkyh.budhrani@dfci.harvard.edu

Received 20 March 2014; Revised 26 May 2014; Accepted 9 June 2014; Published 2 July 2014

Academic Editor: Maria Helena Palucci Marziale

Copyright © 2014 Pinky H. Budhrani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Limited research has been conducted on the moderating effect of race/ethnicity on objective sleep disturbances in breast cancer survivors (BCSs). **Objective.** To explore racial/ethnic differences in objective sleep disturbances among BCSs and their relationship with self-reported symptoms. **Intervention/Methods.** Sleep disturbance and symptoms were measured using actigraphy for 72 hours and self-reported questionnaires, respectively, among 79 BCSs. Analysis of covariance, Pearson's correlation, and multivariate regression were used to analyze data. **Results.** Sixty (75.9%) participants listed their ethnicity as white, non-Hispanic and 19 (24.1%) as minority. Total sleep time was 395.9 minutes for white BCSs compared to 330.4 minutes for minority BCSs. Significant correlations were seen between sleep onset latency (SOL) and depression, SOL and fatigue, and sleep efficiency (SE) and fatigue among minority BCSs. Among white BCSs, significant correlations were seen between SE and pain and wake after sleep onset (WASO) and pain. The association between depression and SOL and fatigue and SOL appeared to be stronger in minority BCSs than white BCSs. **Conclusions.** Results indicate that white BCSs slept longer than minority BCSs, and race/ethnicity modified the effect of depression and fatigue on SOL, respectively. **Implications for Practice.** As part of survivorship care, race/ethnicity should be included as an essential component of comprehensive symptom assessments.

1. Introduction

Breast cancer is the second most commonly diagnosed cancer in the United States and comprises the largest population of cancer survivors, estimated at 2.9 million women and accounting for 22% of all cancer survivors [1]. Advances in breast cancer screening, diagnosis, and treatment have substantially increased the number of breast cancer survivors (BCSs) and with this have highlighted the importance of survivorship needs. A major concern among BCSs is sleep disturbances. BCSs complain of sleep disturbances before, during, and after the completion of treatment negatively affecting their functional status and quality of life [2, 3].

Past research indicates that the prevalence of sleep disturbances in BCSs is 20% higher in comparison to the general population and 32% higher in comparison to patients with gastrointestinal cancer [4, 5]. With the increasing prevalence of sleep disturbances, a standardized assessment to collect and analyze data on sleep is becoming increasingly vital. Previous studies have evaluated the association between symptoms and objective sleep disturbances in patients with breast cancer [6, 7]. These studies have focused primarily on Caucasian women undergoing treatment with limited research among racial/ethnic minorities [8, 9]. Therefore, the goal of this study was to explore the moderating effect of race/ethnicity on objective sleep disturbances and their

a significant predictor of extreme sleep duration (≤ 5 hours and ≥ 9 hours). Compared to whites, blacks were less likely to report sleeping for 7 hours. Extreme sleep durations, decreased sleep efficiency, and increased sleep disruptions are commonly associated with comorbidities, early mortality, and poor health among minority women and women with advanced breast cancer [16, 17]. Increased knowledge of the factors associated with sleep disturbances, including the effect of race/ethnicity on sleep disturbances and their association with symptoms, may improve our understanding of the survivorship experience for patients with cancer.

Past research has indicated that minorities were more likely to experience short sleep durations, lower sleep efficiency, and decreased deep wave sleep [18, 19]. Minority BCSs commonly report sleep-related problems that include sleep maintenance (36%), dissatisfaction with sleep (35.3%), difficulty in falling asleep (23.5%), and early morning awakenings (22.4%) [20]. For patients receiving chemotherapy, whites reported more sleep disturbances than black patients [21]. For patients who have completed treatment, blacks were 44% less likely to report sleep disturbances than whites [22]. The reason for these differences in sleep disturbances is questionable and may be explained either by actual biological differences or by a response bias to questionnaires [23]. Research suggests that an inflammation pathway may mediate the association between decreased sleep duration and cardiometabolic diseases, and this pathway may vary in blacks and whites [24, 25]. Response bias refers to positive reframing, repressive coping, or the modification of responses to sleep questionnaires to be perceived as socially desirable [23]. Blacks may cope with sleep problems within a positive self-regulatory framework, allowing them to deal more effectively with sleep-interfering psychological processes and not perceive sleep disturbances as stressful as other races/ethnicities [26].

Prior research suggests that racial/ethnic disparities exist in the prevalence of symptoms among cancer survivors. In a survey of 139 BCSs, fatigue (76%) was the most commonly reported symptom followed by muscle aches (40%) [27]. Most BCSs complained of greater than six symptoms, and Hispanic women were more likely to report chemotherapy-related symptoms and pain-related symptoms compared to white BCSs. In another study of 199 cancer survivors, black cancer survivors experienced more pain interference, severity, and disability compared to whites [28]. Black BCSs were more likely to have chemotherapy and less likely to have surgery compared to whites. Pain associated with cancer may be associated with an increased morbidity and diminished quality of life for black women consistent with an unequal burden of cancer, pain, and cancer-related chronic pain [28].

Physical symptoms of pain and fatigue commonly co-occur with sleep disturbances. BCSs with fatigue showed significant differences in total sleep time (TST) and wake episodes compared to BCSs without fatigue [29]. Fatigued BCSs also reported worse QOL [30]. In addition, increased pain intensity over time significantly predicted sleep onset latency (SOL) in BCSs [31]. Sleep efficiency (SE) was also significantly lower for BCSs with pain [6]. The night before breast-conserving surgery, BCSs with low SE reported significantly more postoperative pain than BCSs with high SE.

Depression and anxiety are also frequently reported by BCSs. In one study [32] of 67 BCSs, depressed mood significantly predicted subjective sleep quality but not objective sleep in BCSs. Depressive symptoms also have been positively correlated with the prevalence and severity of subjective sleep in BCSs [33]. Anxiety has been correlated with subjective sleep [34], with worse sleep being significantly correlated with increased levels of anxiety in cancer patients. Previous work has demonstrated that black BCSs were less anxious in comparison to white BCSs [35]; this may be associated with higher social support, improved spirituality, and decreased fear of recurrence in black BCSs [36, 37].

We have limited insight on the effect of race/ethnicity on objective sleep disturbances (i.e., sleep actigraphy) and their association with physical and psychological symptoms. The existing gaps in our knowledge point to a need for additional research in this area. Therefore, the purposes of this study were to explore racial/ethnic differences in objective sleep disturbances among BCSs, explore racial/ethnic differences in the associations between objective sleep disturbances with symptoms, and explore the moderating effect of race/ethnicity on the relationship between objective sleep disturbances and symptoms.

4. Method

4.1. Design and Sample. A cross-sectional research design was used to conduct a secondary data analysis of data from the National Cancer Institute (NCI) administrative sleep supplement study of the *MBSR Symptom Cluster Trial for Breast Cancer Survivors/1R01CA131080*. Within the larger study of 322 BCSs, a subsample of 79 completed baseline actigraphic monitoring. Inclusion criteria for the parent study were (1) female gender, age of 21 or older; (2) being diagnosed with stage 0, I, II, or III breast cancer; (3) having completed lumpectomy and/or mastectomy; (4) having from two weeks to two years from the end of treatment with adjuvant radiation and/or chemotherapy; (5) being able to read and speak English at the 8th grade level or above; and (6) having completed baseline actigraphic monitoring and self-reported questionnaires. Exclusion criteria consisted of (1) female gender, with advanced stage breast cancer (stage IV); (2) current diagnosis of severe current psychiatric disorder, and (3) having undergone recurrent treatment for prior breast cancer.

4.2. Setting. Participants were recruited from the H. Lee Moffitt Cancer Center and Research Institute and the Carol and Frank Morsani Center for Advanced Health Care located in Tampa, Florida. Participants enrolled in the study and completed baseline questionnaires in the Survivorship Clinic of the Moffitt Research Center.

4.3. Procedures. The study protocol was approved by the Institutional Review Board at the University of South Florida. A research assistant approached eligible BCSs prior to their scheduled appointment times; if patients were interested, they were invited to an orientation assessment where

informed consent was obtained; they then completed baseline assessment of pain, fatigue, depression, and anxiety through self-reported questionnaires. After the completion of questionnaires, an actigraph was placed on the nondominant wrist of each participant. Participants were asked to continuously wear the actigraph for 72 hours and were provided with safety and care instructions. Participants were also provided with a prestamped, preaddressed envelope for the return of the actigraphy bracelet after 72 hours.

4.4. Instruments. All participants completed questionnaires presented in paper format. A demographic questionnaire queried participants' socioeconomic data including age, race/ethnicity, religion, education, marital status, employment status, and income. Participants completed a clinical history form for data including cancer diagnosis, cancer stage at time of diagnosis, type of breast cancer, length of time since cancer diagnosis, treatment type, and number of weeks on radiation/chemotherapy. Clinical history was verified by medical record review.

Objective sleep disturbances were measured by the Actiwatch Score actigraph (Philips Respironics, Andover, MA), which is a noninvasive method that uses internal motion sensors to capture patient movement data, represented as the number of accelerations per minute [38]. Spans without accelerometer movements reflect sleep. This data is then analyzed to produce a report containing parameters of sleep and wake periods, along with their timing, duration, and other characteristic details. Actigraphy scores correlated with EEG sleep/wake status 95% of the time and with polysomnography (PSG) within a range of ten percent [39].

Sleep disturbance was assessed using (1) SE, (2) SOL, (3) TST, and (4) wake after sleep onset (WASO). SE is defined as the percentage of time in bed spent sleeping [40]. It is calculated by dividing the number of minutes of sleep by the number of minutes in bed, multiplied by 100. SOL is the duration of time from bedtime to falling asleep [40]. TST is defined as the number of minutes of sleep while in bed [40]. WASO refers to the number of minutes awake after sleep onset during the sleep period [40]. All these parameters were measured in this study.

The Fatigue Symptom Inventory (FSI) is a 14-item self-report measure that is designed to assess severity, frequency, daily pattern of fatigue, and perceived interference with QOL [41]. Severity is measured on an 11-point scale (0: not at all; 10: extreme fatigue). Convergent validity and divergent validity were demonstrated with use of correlations with the fatigue scale of the Profile of Mood States Fatigue and the Short-Form General Health Survey (SF-36) vitality subscale [42]. The internal consistency reliability of the four-item FSI severity index in this study was $\alpha = 0.90$.

Pain was measured by the Brief Pain Inventory (BPI) Short Form, which consists of 9 items that measure the severity of pain, impact of pain on daily function, location of pain, pain medications, and amount of pain relief in the past 24 hours or the past week [43]. The mean of the four severity items is used as a measure of pain severity, and the mean of the seven interference items is used as a measure of

pain interference. The internal consistency reliability of the four-item BPI severity scale in this study was $\alpha = 0.94$.

The Center for Epidemiological Studies Depression Scale (CES-D), used to measure depression, is a 20-item instrument that employs a 4-point scale (0: less than 1 day; 3: 5–7 days) to rate how frequently depressive symptoms were experienced during the past week [44]. Measures include cognitive, affective, behavioral, and somatic symptoms of depression and positive effect. The internal consistency reliability of the CES-D in this study was $\alpha = 0.91$. Scores range from 0 to 60 with higher calculated scores indicative of more severe depressive symptoms.

Anxiety was measured with use of the State Trait Anxiety Inventory-State Scale only (STAI-S), a 20-item Likert scale that measures state anxiety ranging from 1 (almost never) to 4 (almost always) [45]. The STAI-S measures an individual's transitional emotional response, including worry, nervousness, tension, and feelings of apprehension to a stressful situation. The internal consistency reliability of the STAI-S in this study was $\alpha = 0.94$. Total scores range from 20 to 80, with higher scores indicative of greater anxiety.

5. Data Analysis

Statistical Product and Services Solutions (SPSS) version 21.0 was utilized for all the deidentified data entry, data management, and analysis for this study. Frequency distributions and descriptive statistics were used to describe the sample demographic and clinical characteristics and actigraphy parameters. *t*-test and chi square analysis were used to compare sample demographic and clinical variables between the white, non-Hispanic, and the minority BCSs. Data analysis was conducted with a two-sided *P* value of less than 0.05 to define statistical significance. All demographic and clinical variables with a *P* value less than 0.05 were included as potential covariates for this analysis. Age was the only variable that was significantly ($P = .041$) different between the two groups and was included as a potential covariate for further analysis. Log transformation was completed to adjust for the skewness of data.

First, race/ethnicity was used to predict actigraphy parameters. The predictor of interest was race/ethnicity (i.e., white, non-Hispanic versus other races/ethnicities) and the defined outcome measures were SE, SOL, TST, and WASO. Analysis of variance (ANOVA) was used initially to compare unadjusted means of the defined outcome variables between the different racial groups, whereas analysis of covariance (ANCOVA) was used to compare adjusted means. The ANCOVA models were adjusted for age, which was a covariate that was imbalanced between the two groups. Secondly, to explore racial/ethnic differences in the associations between actigraphy parameters with physical and psychological symptoms, Pearson correlations were calculated for continuous variables and *t*-tests for variables with two categories. Significant correlations were further analyzed using multiple linear regression analysis with the actigraphy parameter as the dependent variable, race/ethnicity and symptoms as main effect terms, and an interaction term

TABLE 1: Surgery type, treatment type, stage of cancer, type of breast cancer, and time since completion of treatment of participants by race/ethnicity ($N = 79$).

Variable	Total $n = 79$	White, non-Hispanic $n = 60$	Minority $n = 19$	P value
Surgery type, n (%)				0.662
Lumpectomy	34 (43.1)	25 (41.7)	9 (47.4)	
Mastectomy	45 (56.9)	35 (58.3)	10 (52.6)	
Treatment type, n (%)				0.403
Chemotherapy	10 (12.7)	7 (11.7)	3 (15.8)	
Radiation	21 (26.6)	15 (25.0)	6 (31.6)	
Chemotherapy and radiation	23 (29.1)	16 (26.7)	7 (36.8)	
Surgery only	25 (31.6)	22 (36.7)	3 (15.8)	
Cancer stage, n (%)				0.854
0	13 (16.5)	9 (15.0)	4 (21.1)	
1	27 (34.2)	21 (35.0)	6 (31.6)	
2	27 (34.2)	20 (33.3)	7 (36.8)	
3	12 (15.2)	10 (16.7)	2 (10.5)	
Type of breast cancer, n (%)				0.416
Ductal carcinoma in situ	13 (16.5)	9 (15.0)	4 (21.1)	
Invasive lobular	26 (32.9)	20 (33.3)	6 (31.6)	
Invasive ductal	22 (27.8)	18 (30.0)	4 (21.1)	
Not specified	3 (3.8)	1 (1.7)	2 (10.5)	
Unknown	15 (19.0)	12 (20.0)	3 (15.7)	
Time since completion of treatment, n (%)				0.462
2 weeks to 1 year	42 (53.2)	31 (51.7)	11 (57.9)	
1 year to 2 years	37 (46.8)	29 (48.3)	8 (42.1)	

for physical or psychological symptom by race/ethnicity. Separate models were created for each actigraphy parameter. Simultaneous entry was used to enter independent variables in the regression model as the goal was to specifically explore the main effects of physical/psychological symptoms and race/ethnicity, respectively, compared to the interaction effect of physical/psychological symptoms with race/ethnicity on actigraphy parameters.

6. Findings

6.1. Sample Demographics. Of the 79 participants, one participant was a nightshift worker and her actigraphy data was not comparable to the sample and removed from the analysis; however, her remaining data was included. The racial/ethnic mix of the 79 participants was as follows: 60 (75.9%) white, non-Hispanic; 7 (8.9%) white, Hispanic; 8 (10.1%) black, non-Hispanic; 3 (3.8%) black, Hispanic; and 1 (1.3%) listed their ethnicity as other. The mean age of the sample was 55.5 (SD = 9.6) years with a mean age of 58.5 (SD = 8.6) years for white, non-Hispanic BCSs and 52.4 (SD = 11.3) years for minority BCSs. Table 1 shows the treatment related factors for participants. The clinical variables listed in Table 1 were not statistically different by race/ethnicity ($P > 0.05$). Table 2 displays the results summary of actigraphy parameters and physical and psychological symptoms. TST was significantly ($P = 0.039$) different between the groups with a greater

percentage of minority BCSs experiencing TST outside the population norm [13] compared to the white, non-Hispanic group. Though not significantly different, more minority BCSs also experienced SOL and SE outside the population norm and reported higher anxiety, pain, and depression scores.

6.2. Racial/Ethnic Differences in Actigraphy Parameters. The means, standard deviations, mean differences, lower limit, upper limit, P values, and adjusted P values (with age as a covariate) of the actigraphy parameters for the white, non-Hispanic group were compared to those for the minority group (Table 3). Results suggest that TST was significantly higher for white, non-Hispanic participants (395.9 minutes) than for minority participants (330.4 minutes) ($P = 0.01$). In addition, minority participants took 35.7 minutes to fall asleep compared to 22.5 minutes for the white, non-Hispanic women ($P = 0.07$). Another nonsignificant trend for SE to be higher in white, non-Hispanic women (80%) compared to minority women (76%) ($P = 0.09$) was observed.

6.3. Relationship between Actigraphy Parameters and Symptoms. Correlations between the actigraphy parameters and subjective measures of depression (CES-D), fatigue (FSI), pain (BPI), and anxiety (STAI) for the white, non-Hispanic group were compared to those for the minority group (Table 4). Among minority BCSs, significant correlations

TABLE 2: Descriptive statistics of actigraphy parameters, physical and psychological symptoms of participants by race/ethnicity ($N = 78$).

Variables	Minimum	Maximum	Mean	SD	Population normal	Percentage abnormal (white)	Percentage abnormal (minority)	P value
TST	234	582	380.8	62.64	420–540 [13] ^a	63.33	94.44	0.039*
SOL	0	122	25.57	26.13	<20 [13] ^a	48.33	61.11	0.714
SE	56	91	78.76	7.66	>85 [13] ^a	76.67	83.33	0.301
WASO	11	144	61.97	28.11	<42 [13] ^a	83.33	66.67	0.267
STAI	20	78	37.55	11.45	<32.2 [45] ^b	56.67	77.78	0.365
BPI	0	8.75	2.54	2.28	<7 [43] ^c	5.00	11.11	0.187
FSI	0	9	4.03	1.89	≤3 [41] ^d	60.00	38.89	0.922
CES-D	0	55	14.94	10.41	<16 [44] ^e	36.67	38.89	0.863

BPI: Brief Pain Inventory Short Form Severity Scale; CES-D: Center for Epidemiological Studies Depression Scale; FSI: Fatigue Symptom Inventory Severity Scale; SE: sleep efficiency; SOL: sleep onset latency; STAI-S: State Trait Anxiety Inventory-State Scale only; TST: total sleep time; WASO: wake after sleep onset. Data from the ^aAmerican Academy of Sleep Medicine [13], ^bSpielberger et al. [45], ^cCleeland [43], ^dHann et al. [41], ^eRadloff [44].

*Variable is significant at the 0.05 level.

TABLE 3: Means, standard deviations, mean differences, lower and upper limits, and significance of actigraphy parameters of participants by race/ethnicity ($N = 78$).

Actigraphy parameter	Group	<i>n</i>	Mean	Standard deviation	Mean difference	Lower limit	Upper limit	P value	Adjusted P value
TST	Minority	18	330.39	57.47	−65.53	301.81	358.97	0.01	0.01*
	White	60	395.92	56.22	−65.53	381.39	410.44		
SOL	Minority	18	35.69	31.61	13.15	19.97	51.44	0.12	0.07
	White	60	22.53	23.71	13.15	16.41	28.66		
SE	Minority	18	75.93	8.59	−3.68	71.66	80.21	0.07	0.09
	White	60	79.61	7.22	−3.68	77.75	81.48		
WASO	Minority	18	56.22	26.19	−7.48	43.21	69.25	0.33	0.39
	White	60	63.69	28.65	−7.48	56.33	71.11		

SE: sleep efficiency; SOL: sleep onset latency; TST: total sleep time; WASO: wake after sleep onset.

* Actigraphy parameter is significant at the 0.05 level.

were seen between SOL and depression ($r = 0.453$, $P = 0.049$), SOL and fatigue ($r = 0.517$, $P = 0.028$), and SE and fatigue ($r = -0.535$, $P = 0.022$). Among white, non-Hispanic BCSs, significant correlations were seen between SE and pain ($r = -0.316$, $P = 0.014$) and WASO and pain ($r = 0.367$, $P = 0.040$). No significant correlations were seen between anxiety and actigraphy parameters.

6.4. Race/Ethnicity, Actigraphy Parameters, and Symptoms. Table 5 displays the results of the multiple regression analyses for SOL with depression and fatigue, respectively, SE with fatigue and pain, respectively, and WASO with pain. In terms of main effects, pain ($P = 0.017$) had a significant effect on WASO. No main effects of depression or fatigue were found on actigraphy parameters. Race/ethnicity ($P = 0.056$) had a significant main effect on SE only. There was a significant interaction ($\beta = 0.502$, $P = 0.046$) between depression and race/ethnicity on their effect on SOL and a significant interaction ($\beta = 0.596$, $P = 0.033$) between fatigue and race/ethnicity on their effect on SOL.

7. Discussion

To our knowledge, this study is the first to explore racial/ethnic differences in actigraphy parameters and the moderating effect of race/ethnicity on the association between actigraphy parameters and self-reported symptoms among BCSs. The current study yielded three main findings. First, actigraphy parameters indicated that white, non-Hispanic BCSs had better objective sleep compared to minority BCSs. Second, there was evidence of differential associations between symptoms and actigraphy parameters by race/ethnicity. Third, race/ethnicity modified the effect of depression and fatigue on SOL, respectively.

The first aim was to explore racial/ethnic differences in actigraphy parameters among BCSs. Of the actigraphy parameters, TST was significantly ($P = 0.01$) different between the groups with minority BCSs having a lower TST compared to white, non-Hispanic BCSs. Approximately 94% of the minority group had TST outside the accepted range compared to 63% of the white, non-Hispanic group. The National Sleep Foundation [46] poll indicated that blacks

TABLE 4: Correlations between sleep actigraphy parameters and depression, fatigue, pain, and anxiety ($N = 78$).

Actigraphy parameter	Group	<i>n</i>	Depression	Fatigue	Pain	Anxiety
TST	Minority	18	0.014	−0.277	0.236	0.423
	White	60	0.013	−0.129	0.065	0.029
SOL	Minority	18	0.453*	0.517*	0.203	0.281
	White	60	0.160	0.243	0.114	0.081
SE	Minority	18	−0.361	−0.535*	−0.092	−0.107
	White	60	−0.178	−0.106	−0.316*	−0.066
WASO	Minority	18	0.273	0.340	0.048	0.199
	White	60	0.163	0.111	0.367*	0.143

SE: sleep efficiency; SOL: sleep onset latency; TST: total sleep time; WASO: wake after sleep onset.

*Correlations are significant at the 0.05 level.

TABLE 5: Multiple regression analysis of race/ethnicity and symptoms in relation to sleep actigraphy parameters ($N = 78$).

Dependent variable	Primary predictors	Unstandardized coefficient		Standardized coefficients		<i>T</i>	<i>P</i> value	Adjusted <i>R</i> squared
		<i>b</i>	Std. error	β				
SOL (minutes)	Race/ethnicity	−2.72	5.22	−0.091	−0.522	0.603		
	Depression	−0.262	0.505	−0.104	−0.519	0.605		
	Depression by race/ethnicity	0.617	0.304	0.502	2.03	0.046*		0.110
SOL (minutes)	Race/ethnicity	−6.44	6.65	−0.216	−0.968	0.336		
	Fatigue	−2.69	2.81	−0.195	−0.959	0.341		
	Fatigue by race/ethnicity	3.39	1.57	0.596	2.17	0.033*		0.090
SE (percent)	Race/ethnicity	0.722	1.94	0.082	0.372	0.711		
	Fatigue	0.280	0.819	0.069	0.342	0.733		
	Fatigue by race/ethnicity	−0.774	0.456	−0.463	−1.70	0.094		0.101
SE (percent)	Race/ethnicity	−2.62	1.35	−0.299	−1.94	0.056*		
	Pain	−1.14	0.717	−0.339	−1.59	0.117		
	Pain by race/ethnicity	−0.298	0.410	0.177	0.727	0.469		0.064
WASO (minutes)	Race/ethnicity	2.89	4.95	0.090	0.585	0.560		
	Pain	6.43	2.64	0.522	2.44	0.017*		
	Pain by race/ethnicity	−1.98	1.51	−0.322	−1.32	0.192		0.064

SE: sleep efficiency; SOL: sleep-onset latency; WASO: wake after sleep onset.

*Correlations are significant at the 0.05 level.

reported the least amount of sleep, averaging 38 min less sleep than whites. Lower levels of education, increased depressive symptoms, and higher body mass index were associated with short sleep durations of less than 420 minutes [47]. Recent evidence also suggests that residential environment may influence racial/ethnic differences in sleep duration [9].

In addition, there was a trend for SOL to be longer in minority BCSs compared to white, non-Hispanic BCSs. Though not significantly different, 61% of minority BCSs experienced prolonged SOL compared to 48% of white, non-Hispanic BCSs. Furthermore, a greater percentage of minority BCSs experienced decreased SE. These findings can be compared to previous studies that showed blacks slept

for a shorter duration, took longer to fall asleep, and had lower sleep efficiency compared to whites [18, 48]. A recent meta-analysis also indicated similar findings with differences mediated by factors such as adiposity, mental illness, and employment status [49].

The second aim was to explore racial/ethnic differences in the relationships between actigraphy parameters with physical and psychological symptoms. Results suggest that these associations may differ between white, non-Hispanics and minorities. Specifically, depression was directly associated with SOL among minority BCSs; fatigue was directly associated with SOL and inversely associated with SE among minority BCSs; and pain was inversely associated with SE

and directly associated with WASO among white BCSs only. Previous investigators evaluated relationships between symptoms and subjective sleep quality only. The magnitude of the correlations between sleep and fatigue, depression, pain, and anxiety ranged from 0.340 to 0.450, respectively, across seven studies [6, 50, 51]. Contrary to prior findings, TST was not associated with depression or fatigue [15].

The third aim was to explore the moderating effect of race/ethnicity on the relationships between actigraphy parameters and self-reported symptoms. There was no statistically significant effect of race/ethnicity, depression, or fatigue on SOL. However, the combination of depression by race/ethnicity and fatigue by race/ethnicity significantly predicted SOL suggesting that race/ethnicity modified the relationship of depression and fatigue on SOL. This indicates that minority BCSs who are depressed or fatigued may benefit from additional screening to determine if they are experiencing sleep disturbances. Fatigue, depression, and sleep disturbances are the most commonly reported symptoms by minority cancer survivors and often present together as symptom clusters in BCSs [12, 20, 52]. Special consideration should be given to minority BCSs who present with fatigue and depressive symptoms as these symptoms are often underrecognized and undertreated in minority BCSs [20, 53]. Minority cancer survivors showed a reluctance to use the word “depression,” making it more important for providers to assess depression in this population [54]. Several factors may contribute to increased depression in minority BCSs including increased financial barriers, lower social status, and decreased access to mental health services [53]. Cancer-related health worries are also a significant predictor of both depression and anxiety in black BCSs [55]. Early detection and assessment of these symptoms are essential to decrease sleep disturbances among BCSs.

Although race/ethnicity did not modify the effect of fatigue on SE and pain on SE and WASO, respectively, it was helpful in identifying symptoms that were perceived to contribute to sleep disturbances among BCSs. Pain had a significant main effect on WASO and an insignificant main effect on SE. A previous study reported a strong correlation between SE and pain severity among BCSs [6]. Consistent with previous findings, pain was most commonly associated with sleep disturbances among BCSs [56]. Race/ethnicity also had a significant main effect on SE. Past research has indicated that blacks have poorer sleep efficiency compared to whites [16, 49].

7.1. Limitations. Due to the small sample size and imbalanced number of racial/ethnic participants, there may be an underestimation of the strength of a true statistical association (i.e., type II error) or alternatively an overestimation of the effect size and the possibility of type I error. Second, adjustments for multiple comparisons were not completed due to the exploratory nature of the study. Third, the cross-sectional design of the study did not allow for causal relationships between variables to be determined. Of the 79 participants, there were 19 minority patients in the study which represented both blacks and Hispanics. These two groups may

differ in regard to sleep patterns. Future studies should incorporate larger samples of blacks and Hispanics with an attempt to look at differences in sleep patterns between these two groups. Finally, factors that may be associated with differences in actigraphy parameters between races/ethnicities should also be considered. These include demographic risk factors (educational status, employment status, and marital status), clinical factors (medical comorbidities, medications used to treat comorbidities, and the use of sleeping pills), and lifestyle factors (alcohol/cigarette consumption, physical activity, and social support) [15].

7.2. Implications for Research. In addition to exploring changes in sleep disturbances between racial/ethnic groups, the findings of this study may facilitate the development of culturally appropriate, survivorship plans. The National Comprehensive Cancer Network has recently developed guidelines for survivorship care, specifically addressing sleep disorders in cancer survivors. These guidelines can only be generalizable if research is further conducted on minority BCSs. Specifically, longitudinal studies should explore the effect of physical symptoms, psychological symptoms, and race/ethnicity on sleep disturbances. Without such studies, survivorship care plans will be applicable to the white, non-Hispanic population.

This study has several implications for research. Future studies incorporating larger sample sizes with equal representation of white, non-Hispanic BCSs and minority BCSs are needed. In addition, our findings indicate that the relationship between symptoms and sleep disturbances are different by races/ethnicities. Results suggest that depression and fatigue are significant predictors of sleep disturbances among minority BCSs and pain is a significant predictor of sleep disturbances in white, non-Hispanic BCSs. Additional research is needed to evaluate these relationships. Time since completion of treatment did not differ by race/ethnicity, yet this may be an important variable to be further examined in relation to sleep disturbances in BCSs.

Furthermore, longitudinal studies are needed to examine the physical, emotional, and psychosocial contributing factors to shortened TST in minority BCSs compared to white, non-Hispanic BCSs [21]. Fewer hours of sleep has been associated with higher recurrence scores and more aggressive tumors in BCSs [57]. The association of shortened TST and aggressive tumors in minority BCSs should also be further explored. Longitudinal studies implementing longer periods of wrist actigraphy are also required in this population [58]. This study focused on BCSs who remained disease-free after treatment; it is essential that future research also incorporate minority BCSs with recurrent and advanced cancer.

7.3. Implications for Nurses. The subjective and objective assessment of sleep disturbances as part of survivorship care for BCSs is ideal; however, objective assessments may not be feasible in a clinical setting, indicating that practice guidelines assessing sleep are essential. The National Comprehensive Cancer Network (NCCN) guidelines for sleep disorders recommend screening cancer survivors at regular intervals [59].

The following questions are recommended for screening: “do you have difficulty falling or staying asleep,” “how long does it take to fall asleep,” “how many times do you wake up every night,” or “how long have you had difficulty in falling or staying asleep?” If indicated after screening, nurses should conduct comprehensive diagnostic exams including a sleep-oriented history, physical examination, objective testing, and education [60]. Routine assessment of sleep duration should be completed at regular physical exams, specifically for minority BCSs [23]. Inquiring about TST, by asking patients “how many hours are you sleeping at night,” may be more helpful in the identification of BCSs who are at a higher risk of sleep disturbances. Assessments of depression, fatigue, and pain should also be incorporated as part of routine sleep assessment. Culturally appropriate questions during follow-up visits may reduce response bias associated with self-reports, particularly when assessing sleep disturbances and depression in black BCSs [23].

Special consideration should be placed on sleep behaviors among BCSs of different races/ethnicities with attention to sleep hygiene practices, sleep partners, and use of sleep medications. Blacks spend more time in bed without sleeping compared to other ethnic groups and are more likely to report performing activities in the hour before going to bed such as watching TV or praying [46]. Alerting bedtime routines may contribute to increased SOL among minority BCSs. Secondly, a sleep partner could be a contributing factor to sleep disturbances. Asians and Hispanics are more likely to sleep in the same room with their children; whites are more likely to sleep with their significant other; and blacks are most likely to sleep alone [46]. Finally, the use of sleep medications should be considered. Asians are least likely to take sleep medications; whites are more likely to use over-the-counter sleep aids; and blacks are more likely to take prescribed medications.

Nurses are in an ideal position to assess, educate, develop, and integrate evidence-based practice into the management of sleep disturbances among BCSs. Clinical sleep assessments should be a part of comprehensive assessment tools and should be personalized towards minority BCSs. Education provides nurses with the opportunity to teach BCSs about techniques and interventions to manage sleep disturbances. A previous study [61] documented that both black and Hispanic women were not aware of resources for their sleeping problems. Hence, BCSs with sleep disturbances should be informed about interventions for the management of their symptoms and should be encouraged to participate in such interventions, which have been beneficial in addressing symptoms associated with sleep disturbances, including pain, fatigue, and depression [12]. In addition, oncology nurses must collaboratively work with minority BCSs and their families to incorporate sleep hygiene practices and generate shared goals to improve sleep quality in BCSs. Financial barriers, residential and social status, and access to follow-up care should be addressed as these factors may contribute to increased depression and sleep disturbances in minority BCSs [9, 53]. As required, referral to sleep specialists can also be made [9, 59].

8. Conclusion

The study’s findings suggest that minority BCSs have shorter sleep durations compared to white, non-Hispanic BCSs. In addition, pain, fatigue, and depression may be important covariates of sleep disturbances in BCSs. We hypothesize that race/ethnicity modified the association between physical/psychological symptoms and sleep disturbances. As part of survivorship care, race/ethnicity should be included as an essential component of comprehensive symptom assessments in BCSs. Comprehensive sleep assessments including appropriate assessments of pain, fatigue, and depression should be considered when developing and implementing patient centered, culturally appropriate interventions.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors would like to acknowledge Donna Berry, Ph.D. RN, AOCN, FAAN, who provided guidance and support in the paper preparation.

References

- [1] National Cancer Institute, SEER Stat Fact Sheets: Breast, 2013, <http://seer.cancer.gov/statfacts/html/breast.html>.
- [2] K. M. Mustian, L. K. Sprod, M. Janelins et al., “Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors,” *Journal of Clinical Oncology*, vol. 31, no. 26, pp. 3233–3241, 2013.
- [3] G. Kotronoulas, Y. Wengström, and N. Kearney, “A critical review of women’s sleep-wake patterns in the context of neo-/adjuvant chemotherapy for early-stage breast cancer,” *Breast*, vol. 21, no. 2, pp. 128–141, 2012.
- [4] J. Savard, S. Simard, J. Blanchet, H. Ivers, and C. M. Morin, “Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer,” *Sleep*, vol. 24, no. 5, pp. 583–590, 2001.
- [5] P. N. Schultz, M. J. Klein, M. L. Beck, C. Stava, and R. V. Sellin, “Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors,” *Journal of Clinical Nursing*, vol. 14, no. 2, pp. 204–211, 2005.
- [6] C. E. Wright, D. H. Bovbjerg, G. H. Montgomery et al., “Disrupted sleep the night before breast surgery is associated with increased postoperative pain,” *Journal of Pain and Symptom Management*, vol. 37, no. 3, pp. 352–362, 2009.
- [7] L. Liu, M. Rissling, L. Natarajan et al., “The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy,” *Sleep*, vol. 35, no. 2, pp. 237–245, 2012.
- [8] S. Redline, H. L. Kirchner, S. F. Quan, D. J. Gottlieb, V. Kapur, and A. Newman, “The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture,” *Archives of Internal Medicine*, vol. 164, no. 4, pp. 406–418, 2004.

- [9] L. Hale and D. P. Do, "Racial differences in self-reports of sleep duration in a population-based study," *Sleep*, vol. 30, no. 9, pp. 1096–1103, 2007.
- [10] M. Dodd, S. Janson, N. Facione et al., "Advancing the science of symptom management," *Journal of Advanced Nursing*, vol. 33, no. 5, pp. 668–676, 2001.
- [11] J. Humphreys, S. Janson, D. Donesky et al., *Middle Range Theory for Nursing*, Springer, New York, NY, USA, 3rd edition, 2014.
- [12] C. A. Lengacher, R. R. Reich, J. Post-White et al., "Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters," *Journal of Behavioral Medicine*, vol. 35, no. 1, pp. 86–94, 2012.
- [13] American Academy of Sleep Medicine, *International Classification of Sleep Disorders: Diagnostic & Coding Manual*, American Academy of Sleep Medicine, Westchester, Ill, USA, 2nd edition, 2005.
- [14] L. Fiorentino, M. Rissling, L. Liu, and S. Ancoli-Israel, "The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: severity of the problem and treatment options," *Drug Discovery Today: Disease Models*, vol. 8, no. 4, pp. 167–173, 2011.
- [15] K. M. Phillips, H. S. Jim, K. A. Donovan, M. C. Pinder-Schenck, and P. B. Jacobsen, "Characteristics and correlates of sleep disturbances in cancer patients," *Supportive Care in Cancer*, vol. 20, no. 2, pp. 357–365, 2012.
- [16] J. Nunes, G. Jean-Louis, F. Zizi et al., "Sleep duration among black and white Americans: results of the National Health Interview Survey," *Journal of the National Medical Association*, vol. 100, no. 3, pp. 317–322, 2008.
- [17] O. Palesh, A. Aldridge-Gerry, and J. M. Zeitzer, "Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer," *Sleep*, vol. 37, no. 5, pp. 837–842, 2014.
- [18] E. J. Mezick, K. A. Matthews, M. Hall et al., "Influence of race and socioeconomic status on sleep: pittsburgh SleepSCORE project," *Psychosomatic Medicine*, vol. 70, no. 4, pp. 410–416, 2008.
- [19] D. S. Lauderdale, K. L. Knutson, L. L. Yan, K. Liu, and P. J. Rathouz, "Self-reported and measured sleep duration: how similar are they?" *Epidemiology*, vol. 19, no. 6, pp. 838–845, 2008.
- [20] T. R. Taylor, E. D. Huntley, K. Makambi et al., "Understanding sleep disturbances in African-American breast cancer survivors: a pilot study," *Psycho-Oncology*, vol. 21, no. 8, pp. 896–902, 2012.
- [21] E. D. Paskett, C. M. Alfano, M. A. Davidson et al., "Breast cancer survivors' health-related quality of life: racial differences and comparisons with noncancer controls," *Cancer*, vol. 113, no. 11, pp. 3222–3230, 2008.
- [22] O. G. Palesh, J. A. Roscoe, K. M. Mustian et al., "Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester cancer center-community clinical oncology program," *Journal of Clinical Oncology*, vol. 28, no. 2, pp. 292–298, 2010.
- [23] B. Adenekan, A. Pandey, S. McKenzie, F. Zizi, G. J. Casimir, and G. Jean-Louis, "Sleep in America: role of racial/ethnic differences," *Sleep Medicine Reviews*, vol. 17, no. 4, pp. 255–262, 2013.
- [24] S. G. Buxbaum, R. C. Elston, P. V. Tishler, and S. Redline, "Genetics of the apnea hypopnea index in Caucasians and African Americans: I. Segregation analysis," *Genetic Epidemiology*, vol. 22, no. 3, pp. 243–253, 2002.
- [25] L. Simpson, S. Mukherjee, M. N. Cooper et al., "Sex differences in the association of regional fat distribution with the severity of obstructive sleep apnea," *Sleep*, vol. 33, no. 4, pp. 467–474, 2010.
- [26] J. D. Edinger, M. H. Bonnet, R. R. Bootzin et al., "Derivation of research diagnostic criteria for insomnia: report of an American academy of sleep medicine work group," *Sleep*, vol. 27, no. 8, pp. 1567–1596, 2004.
- [27] O. S. Fu, K. D. Crew, J. S. Jacobson et al., "Ethnicity and persistent symptom burden in breast cancer survivors," *Journal of Cancer Survivorship: Research and Practice*, vol. 3, no. 4, pp. 241–250, 2009.
- [28] C. R. Green, T. Hart-Johnson, and D. R. Loeffler, "Cancer-related chronic pain," *Cancer*, vol. 117, no. 9, pp. 1994–2003, 2011.
- [29] S. Alexander, O. Minton, P. Andrews, and P. Stone, "A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome," *European Journal of Cancer*, vol. 45, no. 3, pp. 384–392, 2009.
- [30] S. R. Dirksen, M. J. Belyea, and D. R. Epstein, "Fatigue-based subgroups of breast cancer survivors with insomnia," *Cancer Nursing*, vol. 32, no. 5, pp. 404–411, 2009.
- [31] O. G. Palesh, K. Collie, D. Batiuchok et al., "A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer," *Biological Psychology*, vol. 75, no. 1, pp. 37–44, 2007.
- [32] C. A. Enderlin, E. A. Coleman, C. Cole et al., "Subjective sleep quality, objective sleep characteristics, insomnia symptom severity, and daytime sleepiness in women aged 50 and older with nonmetastatic breast cancer," *Oncology Nursing Forum*, vol. 38, no. 4, pp. E314–E325, 2011.
- [33] J. L. Otte, J. S. Carpenter, K. M. Russell, S. Bigatti, and V. L. Champion, "Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors," *Journal of Pain and Symptom Management*, vol. 39, no. 3, pp. 535–547, 2010.
- [34] M. Delgado-Guay, S. Yennurajalingam, H. Parsons, J. L. Palmer, and E. Bruera, "Association between self-reported sleep disturbance and other symptoms in patients with advanced cancer," *Journal of Pain and Symptom Management*, vol. 41, no. 5, pp. 819–827, 2011.
- [35] P. E. Lewis, M. Sheng, M. M. Rhodes, K. E. Jackson, and L. R. Schover, "Psychosocial concerns of young African American breast cancer survivors," *Journal of Psychosocial Oncology*, vol. 30, no. 2, pp. 168–184, 2012.
- [36] T. R. Taylor, E. D. Huntley, J. Sween et al., "An exploratory analysis of fear of recurrence among African-American breast cancer survivors," *International Journal of Behavioral Medicine*, vol. 19, no. 3, pp. 280–287, 2012.
- [37] T. Thompson, T. L. Rodebaugh, M. Perez, M. Schootman, and D. B. Jeffe, "Perceived social support change in patients with early stage breast cancer and controls," *Health Psychology*, vol. 32, no. 8, pp. 886–895, 2013.
- [38] J. F. Grutsch, P. A. Wood, J. Du-Quito et al., "Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer," *Journal of Circadian Rhythms*, vol. 9, article 4, 2011.
- [39] J. B. Webster, D. F. Kripke, S. Messin, D. J. Mullaney, and G. Wyborney, "An activity-based sleep monitor system for ambulatory use," *Sleep*, vol. 5, no. 4, pp. 389–399, 1982.
- [40] American Academy of Sleep Medicine, "International classification of sleep disorders, revised: Diagnostic and coding manual," 2013, <http://www.esst.org/adds/ICSD.pdf>.

- [41] D. M. Hann, P. B. Jacobsen, L. M. Azzarello et al., "Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory," *Quality of Life Research*, vol. 7, no. 4, pp. 301–310, 1998.
- [42] P. B. Jacobsen, "Assessment of fatigue in cancer patients," *Journal of the National Cancer Institute. Monographs*, no. 32, pp. 93–97, 2004.
- [43] C. S. Cleeland, "Pain assessment in cancer," in *Effect of Cancer on Quality of Life*, D. Osoba, Ed., pp. 293–305, CRC Press, Boca Raton, Fla, USA, 1991.
- [44] L. S. Radloff, "The CES-D scale: a self-report depression scale for researching the general population," *Application of Psychological Measures*, vol. 1, pp. 385–401, 1977.
- [45] C. D. Spielberger, R. L. Gorsuch, R. Lushene, P. R. Vagg, and G. A. Jacobs, *Manual for the State-Trait Anxiety Inventory*, CA Consulting Psychologists Press, Palo Alto, Calif, USA, 1983.
- [46] National Sleep Foundation, Poll Reveals Sleep Differences among Ethnic Groups, 2010, <http://sleepfoundation.org/media-center/press-release/poll-reveals-sleep-differences-among-ethnic-groups/page/0%2C4/>.
- [47] A. A. Gamaldo, J. M. McNeely, M. T. Shah, M. K. Evans, and A. B. Zonderman, "Racial differences in self-reports of short sleep duration in an urban-dwelling environment," *The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences*, 2013.
- [48] D. S. Lauderdale, K. L. Knutson, L. L. Yan et al., "Objectively measured sleep characteristics among early-middle-aged adults: the CARDIA study," *The American Journal of Epidemiology*, vol. 164, no. 1, pp. 5–16, 2006.
- [49] M. E. Ruiter, J. DeCoster, L. Jacobs, and K. L. Lichstein, "Normal sleep in African-Americans and Caucasian-Americans: a meta-analysis," *Sleep Medicine*, vol. 12, no. 3, pp. 209–214, 2011.
- [50] K. A. Donovan and P. B. Jacobsen, "Fatigue, depression, and insomnia: evidence for a symptom cluster in cancer," *Seminars in Oncology Nursing*, vol. 23, no. 2, pp. 127–135, 2007.
- [51] M. Nishiura, A. Tamura, H. Nagai, and E. Matsushima, "Assessment of sleep disturbance in lung cancer patients: relationship between sleep disturbance and pain, fatigue, quality of life, and psychological distress," *Palliative and Supportive Care*, pp. 1–7, 2014, 10.1017/S1478951513001119.
- [52] J. M. Finney, J. B. Hamilton, E. A. Hodges, B. J. Pierre-Louis, J. L. Crandell, and H. B. Muss, "African American cancer survivors: do cultural factors influence symptom distress?" *Journal of Transcultural Nursing*, 2014.
- [53] V. B. Sheppard, A. A. Llanos, A. Hurtado-de-Mendoza, T. R. Taylor, and L. L. Adams-Campbell, "Correlates of depressive symptomatology in African-American breast cancer patients," *Journal of Cancer Survivorship*, vol. 7, no. 3, pp. 292–299, 2013.
- [54] A. Y. Zhang and F. Gary, "Discord of measurements in assessing depression among African Americans with cancer diagnoses," *International Journal of Culture and Mental Health*, vol. 6, no. 1, pp. 58–71, 2013.
- [55] G. T. Deimling, K. F. Bowman, S. Sterns, L. J. Wagner, and B. Kahana, "Cancer-related health worries and psychological distress among older adult, long-term cancer survivors," *Psycho-Oncology*, vol. 15, no. 4, pp. 306–320, 2006.
- [56] A. M. Berger, C. Visovsky, M. Hertzog, S. Holtz, and F. R. Loberiza Jr., "Usual and worst symptom severity and interference with function in breast cancer survivors," *Journal of Supportive Oncology*, vol. 10, no. 3, pp. 112–118, 2012.
- [57] C. L. Thompson and L. Li, "Association of sleep duration and breast cancer OncotypeDX recurrence score," *Breast Cancer Research and Treatment*, vol. 134, no. 3, pp. 1291–1295, 2012.
- [58] J. Savard, L. Liu, L. Natarajan et al., "Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy," *Sleep*, vol. 32, no. 9, pp. 1155–1160, 2009.
- [59] National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Survivorship, 2014, http://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf.
- [60] L. J. Epstein, D. Kristo, P. J. Strollo Jr. et al., "Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults," *Journal of Clinical Sleep Medicine*, vol. 5, no. 3, pp. 263–276, 2009.
- [61] J. Yoon, J. L. Malin, D. M. Tisnado et al., "Symptom management after breast cancer treatment: is it influenced by patient characteristics?" *Breast Cancer Research and Treatment*, vol. 108, no. 1, pp. 69–77, 2008.